View all newsletters
Receive our newsletter – data, insights and analysis delivered to you

Stroke accounts for 12.6% share of global Cardiovascular clinical trial activity in 2020

Stroke accounted for a 12.6% share of the global clinical trials within the Cardiovascular therapy area in 2020, registering an increase of 3.3% when compared with the last ten-year average of 9.3% share, according to GlobalData.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Non-industry sponsored trials outnumber industry sponsored trials for Stroke

Industry sponsored trials held a 49.1% share of all the clinical trials for Stroke indication in 2020, registering an increase of 16.6% when compared with the ten-year average of 32.5%. Non-industry sponsored trials accounted for a 50.9% share in 2020, marking a decrease of 16.6% over the ten-year average of 67.5%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Top regions of industry sponsored Stroke trials

Asia-Pacific was the top region for industry sponsored Stroke trials, accounting for a 60.2% share in 2020, when compared with the five-year average of 57.7% and ten-year average of 52.3%.

Europe was at the second position with a 35.9% share in 2020, over the five-year average of 36.7% and ten-year average of 42.3%, followed by North America with a 10.7% share in 2020, as against five-year and ten-year averages of 19.4% and 25.9% respectively.

Middle East and Africa stood fourth with a 1.0% share in 2020, compared with the five-year average of 6.1% and ten-year average of 10.1%, followed by South and Central America with a 0.0% share in 2020, over five-year and ten-year averages of 4.1% and 7.1% respectively.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

China was the top country for industry sponsored Stroke trials, accounting for a 43.7% share in 2020, as against the five-year average of 27.9% and ten-year average of 21.7%.

Russia held a 23.3% share in 2020, over the five-year average of 18.6% and ten-year average of 22.7%, followed by the US with an 8.7% share in 2020, compared with the five-year and ten-year averages of 17.7% and 24.2% respectively.

Australia held a 5.8% share in 2020, as against the five-year average of 7.0% and ten-year average of 7.7%.

Canada held a 5.8% share in 2020, over the five-year and ten-year averages of 8.2% and 11.6% respectively.

Top regions of non-industry sponsored Stroke trials

Asia-Pacific was the top region for non-industry sponsored Stroke trials, accounting for a 67.6% share in 2020 when compared with the five-year average of 55.2% and ten-year average of 53.7%.

Europe was at the second position with a 14.7% share in 2020, over the five-year and ten-year averages of 20.2% and 23.7% respectively, followed by North America with a 14.7% share in 2020, as against the five-year average of 15.8% and ten-year average of 17.1%.

Middle East and Africa stood at the fourth position with a 5.9% share in 2020, compared with the five-year average of 13.2% and ten-year average of 10.6%, followed by South and Central America with a 0.0% share in 2020, over the five-year and ten-year averages of 2.1% and 2.4% respectively.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

China was the top country for non-industry sponsored Stroke trials, accounting for a 49.0% share in 2020, as against the five-year average of 35.4% and ten-year average of 28.2%.

The US held a 10.8% share in 2020, over the five-year average of 11.4% and ten-year average of 12.7%, followed by Australia with a 5.9% share, compared with the five-year and ten-year averages of 5.0% and 4.9% respectively.

Iran held a 5.9% share in 2020, as against the five-year average of 9.2% and ten-year average of 7.7%.

The Netherlands held a 4.9% share in 2020, over the five-year average of 2.4% and ten-year average of 3.4%.

Phase I trials lead industry sponsored clinical trials for Stroke in 2020

Phase I trials held a 69.2% share of industry sponsored clinical trials for Stroke in 2020, over the five-year average of 44.6% and ten-year average of 41.1%.

Phase II trials held a 15.0% share in 2020, as against the five-year average of 22.2% and ten-year average of 19.4%. Phase IV trials held an 8.4% share in 2020, compared with the five-year and ten-year averages of 16.9% and 19.4% respectively.

Phase III trials held a 7.5% share in 2020, over the five-year average of 16.3% and ten-year average of 20.0%.

Phase II trials lead non-industry sponsored clinical trials for Stroke in 2020

Phase II trials held a 34.2% share of non-industry sponsored clinical trials for Stroke in 2020, over the five-year average of 40.7% and ten-year average of 40.8%.

Phase IV trials held a 29.7% share in 2020, as against the five-year average of 30.9% and ten-year average of 30.0%. Phase III trials held a 19.8% share, compared with the five-year and ten-year averages of 19.9% and 20.3% respectively.

Phase I trials held a 16.2% share in 2020, over the five-year average of 8.4% and ten-year average of 9.0%.

Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU